Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1306 plus XELOX in EBV-associated advanced gastric cancer
ChiCTR1900022184Phase 2Not yet recruiting
- Sponsor
- People's Liberation Army 81 Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bat1306, capecitabine and oxaliplatin in Epstein-Barr virus-associated gastric cancer (EBVaGC), sponsored by People's Liberation Army 81 Hospital. Primary endpoints: Objective response rate, Disease control rate and 2 more. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
bat1306capecitabineoxaliplatin
03
Conditions
Epstein-Barr virus-associated gastric cancer (EBVaGC)
Beyond the preview
Go deeper on ChiCTR1900022184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022184.